Emerging research suggest Retatrutide , a dual agonist targeting both incretin and another hormone, may offer a notable advancement for obesity loss . Initial human tests have indicated impressive losses in body tissue, possibly exceeding existing body composition therapies . Despite this, more study is necessary to completely determine its sustain